WO2001042233A1 - Derives de chromane et de thiochromane optiquement actifs - Google Patents
Derives de chromane et de thiochromane optiquement actifs Download PDFInfo
- Publication number
- WO2001042233A1 WO2001042233A1 PCT/JP2000/008807 JP0008807W WO0142233A1 WO 2001042233 A1 WO2001042233 A1 WO 2001042233A1 JP 0008807 W JP0008807 W JP 0008807W WO 0142233 A1 WO0142233 A1 WO 0142233A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound represented
- reaction
- compound
- hydrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/38—2,3-Dihydro derivatives, e.g. isoflavanones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Definitions
- the present invention relates to an optically active chroman or chiochroman derivative having anti-estrogenic activity.
- the effects induced by this sex steroid hormone can be significantly suppressed, or more preferably completely. Is very important.
- a method of administering an anti-estrogenic drug to limit it to less than that required for body site activation is used.
- this prior art method for blocking estrogen production was not able to sufficiently suppress the effects induced through the estrogen receptor. In fact, some receptors can be activated even in the absence of estrogen at all.
- the estrogen antagonist could provide better therapeutic results as compared to the method that blocks only the production of sex steroid hormones.
- various estrogen antagonists have been developed.
- various anti-estrogenic compounds are disclosed in many patent documents including U.S. Pat.Nos. 4,760,061, 4,732,912, 4,904,661, 5,395,842 and WO 96/22092.
- prior art antagonists may in some cases also act as agonists themselves, thus activating rather than blocking the receptor.
- tamoxifen is the most widely used antiestrogenic drug, but has some problems such as showing estrogenic activity in some organs (see: M. Harper and A. Walpole, J. Reprod. Fertil ., 1967, 13, 101).
- WO 9310741 discloses a benzopyran derivative having an aminoethoxyphenyl substituent (Endorecherche).
- the compounds include EM-343 and the like having the following structure, and these compounds also have an agonist effect. Therefore, there is a need for the development of antiestrogenic compounds that have substantially no or no agonist effect and that can effectively block estrogen receptors.
- a 7 ⁇ -substituted derivative of estradiol for example, a ⁇ CH ⁇ uCONMeBu derivative
- exhibits an antiestrogenic action see European Patent.
- a 7 ⁇ -substituted derivative of estradiol a 7 ⁇ - (CH 2 ) 9 SOC 5 H 6 F 5 derivative is also disclosed.
- Non-steroidal anti-estrogenic drugs without agonist effects were first reported by Wakeling et al. In 1987 (see: A. Wakeling and Bowler, J. Endocrinol., 1987, 112, R7).
- the publication of U.S. Pat. No. 4,904,661 discloses a phenol derivative having anti-estrogenic activity. This phenol derivative generally has a naphthalene skeleton, and typical compounds include the following compounds.
- anti-estrogenic compounds having no agonist action are also known for chroman derivatives and thiochroman derivatives, which are disclosed in W098 / 25916.
- anti-estrogen compounds having no agonist action which have been hitherto known, are expected to have a considerable therapeutic effect when administered directly or subcutaneously intravenously, but have a low therapeutic effect when administered orally.
- One of the reasons may be low bioavailability. Therefore, considering the convenience in prescribing a drug, it is desirable to develop an anti-estrogen compound having no agonist action and exhibiting a sufficiently strong effect even in oral administration. Disclosure of the invention
- An object of the present invention is to provide an optically active compound having excellent anti-estrogenic activity, which is a chroman or thiochroman derivative having an asymmetric point, which is useful as a medicament.
- the present inventors studied the antiestrogenic activity of compounds having various structures. did. As a result, pharmaceuticals such as optically active chroman or thiochroman derivatives represented by the general formulas (1) to (4) can exhibit more prominent anti-estrogenic activity as compared with the corresponding diastereomeric mixture. As a result, they have found that the present invention can be more preferable, and have completed the present invention.
- the present invention provides a compound represented by the general formula (1):
- X represents an oxygen atom or a sulfur atom
- m represents an integer of 2 to 14
- n represents an integer of 2 to 7
- a hydrate thereof That is what you do.
- the present invention relates to a compound represented by the general formula (1) or (2), wherein a carbon atom to which a carboxylic acid of a side chain bonded to the 4-position of the mother nucleus (chroman ring or thiochroman ring) is bonded. Or to provide an optically single isomer in S configuration, and mixtures thereof.
- the present invention provides a medicine containing an optically active compound represented by the general formula (1), (2), (3) or (4) as an active ingredient. Further, the present invention provides a pharmaceutical composition having an anti-estrogenic activity, comprising the above-mentioned compound as an active ingredient. The present invention also provides a therapeutic agent for breast cancer containing the above compound as an active ingredient.
- m is preferably 6 to 10, and particularly preferably 8 or 9.
- n is preferably any of 2 to 7, particularly preferably 3 or 4.
- the configuration at the 3- and 4-positions of the mother nucleus is (3S, 4S) or (3R, 4R), respectively.
- 3S, 4S the configuration at the 3- and 4-positions of the mother nucleus
- 3R, 4R the configuration at the 3- and 4-positions of the mother nucleus
- any of these compounds is preferred.
- Compounds of the formula are more preferred.
- a compound represented by the general formula (2) is preferred (particularly preferred when X is a sulfur atom).
- Another embodiment of the present invention is a compound represented by the general formula (1) or (2), wherein X is an oxygen atom.
- a compound in which X is an oxygen atom or a sulfur atom; m is 8 or 9; n is 3 or 4 is preferable. Further preferred are compounds having an R or S configuration with respect to the carbon to which the carboxylic acid of the side chain bonded to the 4-position is bonded.
- the compounds of the present invention can also be obtained as hydrates.
- the compound represented by the general formula (1), (2), (3) or (4) may be one or more pharmaceutically acceptable diluents, wetting agents, emulsifiers, dispersants, and auxiliaries. It can be administered as a pharmaceutical composition containing a preservative, a buffer, a binder, a stabilizer and the like in any appropriate form depending on the intended route of administration.
- the route of administration may be parenteral or oral.
- the dose of the compound of the present invention can be appropriately selected depending on the patient's body type, age, physical condition, degree of disease, elapsed time after onset, and the like, but higher drug efficacy can be expected as compared to the corresponding diastereomeric mixture. Therefore, drug efficacy can be expected with a smaller dose.
- oral administration it is generally used at a dose of 0.1 to 500 mg / day Zperson, and in the case of parenteral administration (intravenous, intramuscular, subcutaneous), it is generally 1 to 100 mg / day. Used at the dose of OmgZmonth / person.
- the compound represented by the general formula (1) or (2) can be produced by the method shown in any of the following reaction schemes 1 to 10 (methods 1 to 10).
- reaction schemes 1 to 10 compounds with an asterisk (*, for example, ( ⁇ ) for compound (I)) have the following meanings.
- the compound represented by the general formula (3) or (4) can be used as a starting material in the method shown in any of the following reaction schemes 1 to 10 (methods 1 to 10) as a starting material.
- reaction formulas 1, 6 racemic (XII) (Reaction 2), racemic (VII) (Reaction 3), racemic (XV II) (Reactions 4, 5), XXV (Reaction 7 ), Racemic form (XX IX) (Reaction formula 8, 9), optically active form (XXXV *, XXXV I *)
- Reaction Scheme 2 (Method 2) —
- reaction Scheme 3 (Method 3), X, m, n is the general formula (1) are as defined in ⁇ (4); R u, R 13 represents a protecting group; represents a leaving group.
- Racemic (I) is converted to a chiral column (eg, CHIRALPAK-OT (I), 0P (+), AD, CHIRALC EL-OA, OB, 0J, OK, OC, OD, OF, OG, etc. (trade name: manufactured by Daicel Corporation) )) To obtain an optically active compound represented by the formula (1 *).
- a chiral column eg, CHIRALPAK-OT (I), 0P (+), AD, CHIRALC EL-OA, OB, 0J, OK, OC, OD, OF, OG, etc. (trade name: manufactured by Daicel Corporation)
- a base eg, n-butyllithium, s-butyllithium, sodium hydride
- a solvent inert to the reaction eg, tetrahydrofuran, getyl ether, dioxane, dichloromethane, dichloromethane, preferably In tetrahydrofuran or dioxane
- the compound represented by the formula (1 *) (II) to give a compound represented by the formula (II 1).
- a Lewis acid such as zinc iodide
- a solvent inert to the reaction eg, tetrahydrofuran, getyl ether, dioxane, dichloromethane, dichloroethane or chloroform, preferably dichloroethane.
- a Lewis acid such as zinc iodide
- the compound represented by the formula (II 1 *) is treated with sodium cyanoborohydride (N aBH 3 CN) to give a compound of formula (IV *).
- a solvent inert to the reaction eg methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane, preferably tetrahydrofuran, ethyl acetate
- a catalyst eg, palladium on activated carbon, palladium hydroxide, platinum oxide
- the compound represented by the formula (V *) can be prepared in a solvent inert to the reaction (eg, methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane, preferably tetrahydrofuran, ethyl acetate) at room temperature. And directly at the temperature between the boiling points of the reaction mixture, preferably at room temperature, by a hydrogenation reaction using a catalyst (eg palladium on activated carbon, palladium hydroxide or platinum oxide) by the formula (III *) directly. It can also be obtained from a compound.
- a solvent inert eg, methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane, preferably tetrahydrofuran, ethyl acetate
- a catalyst eg palladium on activated carbon, palladium hydroxide or platinum oxide
- a solvent inert to the reaction eg, tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably dichloromethane
- a base eg, triethylamine or pyridine
- the formula (VI *) a compound represented by the treatment with methanesulfonyl chloride or p- toluenesulfonic Srn ⁇ torque chloride de formula group (VI *) of the compound (CH 2 ) m OH to (CH 2 ) m O—S ⁇ 2 CH 3 or (CH 2 ) m O—S ⁇ 2 — C 6 H 4 — p— CH 3
- a solvent inert to the reaction for example, acetone, tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably acetone.
- a base eg, sodium hydride, sodium hydroxide, or potassium t-butoxide
- a solvent inert to the reaction eg, tetrahydrofuran, getyl ether, dioxane, dimethylformamide, dichloromethane, dichlorobenzene.
- the compound represented by the formula (XIV *) may be synthesized from the compound represented by the formula (XII *) as follows. The same procedure as in the above method 1 is performed up to the production of the compound represented by the formula (XII *).
- the compound represented by the formula (XIV *) can also be obtained from the compound represented by the formula (VI1 *) as follows.
- a solvent inert to the reaction for example, tetrahydrofuran, dioxane, dimethylformamide, dichloromethane, dichloroethane or chloroform.
- a solvent inert to the reaction for example, tetrahydrofuran, dioxane, dimethylformamide, dichloromethane, dichloroethane or chloroform.
- the compound represented by the formula (XIV *) may be produced as follows. In the presence of a catalyst such as benzylidene-bis (tricyclohexylphosphine) dichlororuthenium, in a solvent (eg, methylene chloride, chloroform, benzene, toluene, xylene, dioxane, tetrahydrofuran, dimethylsulfoxide or dimethylformamide) Reacting the compound represented by the formula (XV II *) with the compound represented by the formula (XV III) at a temperature between ⁇ 78 t and the boiling point of the reaction mixture, preferably at the boiling point of the reaction mixture; A compound represented by the formula (XIX *) is obtained.
- a catalyst such as benzylidene-bis (tricyclohexylphosphine) dichlororuthenium
- Solvents inert to the reaction eg, methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane, dichloromethane, dichloroethane, Hydrogenation in a catalyst (eg palladium on activated carbon, palladium hydroxide, platinum oxide or Wilkinson catalyst) at room temperature and at a temperature between the boiling points of the reaction mixture, preferably at room temperature,
- a catalyst eg palladium on activated carbon, palladium hydroxide, platinum oxide or Wilkinson catalyst
- the compound represented by the formula (XIV *) may be further produced as follows.
- a catalyst such as benzylidene-bis (tricyclohexylphosphine) dichlororuthenium
- a solvent eg, methylene chloride, chloroform, benzene, toluene, xylene, dioxane, tetrahydrofuran, dimethylsulfoxide or dimethylformamide
- a solvent eg, methylene chloride, chloroform, benzene, toluene, xylene, dioxane, tetrahydrofuran, dimethylsulfoxide or dimethylformamide
- a solvent inert to the reaction e.g. methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane, dichloromethane, dichloroethane or benzene
- a catalyst e.g, palladium on activated carbon, palladium hydroxide, platinum oxide or Wilkinson's catalyst
- a compound represented by the formula (XXIII *) (the same as the compound of the formula (XI *) in the method 1) is converted into a compound described by the method 1 or the method 2 (the compound represented by the formula (XI *) (Method for converting to compound represented by XIV *)) In the same manner as in (4), the compound is converted to a compound represented by formula (XIV *).
- X is as defined in general formulas (1) and (4); R juryrepresents a protecting group; and L 3 represents a leaving group.
- a solvent inert to the reaction eg dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform
- the temperature between -78T: and the boiling point of the reaction mixture preferably Is reacted at 0 ° C to room temperature with a compound represented by the formula (XXV) and aryltrimethylsilane in the presence of anhydrous TBAF (with the addition of HMPA if necessary), VI) is obtained.
- the compound represented by the formula (XXV II) is reacted in a solvent inert to the reaction (eg, tetrahydrofuran, dioxane, or getylether) at a temperature between 178 ° C and the boiling point of the reaction mixture.
- a solvent inert e.g, tetrahydrofuran, dioxane, or getylether
- a solvent inert to the reaction eg toluene, dioxane, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dichloromethane, dichloroethane or chloroform
- a solvent inert to the reaction eg toluene, dioxane, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dichloromethane, dichloroethane or chloroform
- the compound represented by the formula (XIV *) obtained by the above methods 1 to 5 has a hydroxyl group, it can be converted to a salt form.
- Preferred pharmaceutically acceptable salts include sodium salt, potassium salt, calcium salt, magnesium salt and the like.
- a salt of the compound represented by the formula (XIV *) can be produced as follows.
- Benzylidene in the presence of a catalyst such as bis (tricyclohexylphosphine) dichlororuthenium in a solvent eg, methylene chloride, chloroform, benzene, toluene, xylene, dioxane, tetrahydrofuran, dimethylsulfoxide or dimethylformamide
- a catalyst such as bis (tricyclohexylphosphine) dichlororuthenium
- a solvent eg, methylene chloride, chloroform, benzene, toluene, xylene, dioxane, tetrahydrofuran, dimethylsulfoxide or dimethylformamide
- Catalysts eg, palladium on activated carbon, palladium hydroxide, platinum oxide or Temperature
- a solvent eg, methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane or benzene
- the compound represented by the formula (XXXI *) is hydrogenated at room temperature, preferably, to obtain a reduced form.
- a solvent for example, a mixed solvent of tetrahydrofuran / water, a mixed solvent of getyl ether / water, a mixed solvent of dioxane / water, a mixed solvent of methanol / water, and ethanol
- Water mixed solvent at room temperature and at a temperature between the boiling points of the reaction mixture, preferably at room temperature, lithium hydroxide, sodium hydroxide, lithium hydroxide + hydrogen peroxide, sodium hydroxide + hydrogen peroxide, tetra Treatment with butylammonium hydroxide + hydrogen peroxide gives the compound represented by the formula (XXXII *).
- a catalyst eg, palladium on activated carbon, palladium hydroxide, platinum oxide or a Wilkinson catalyst
- a solvent inert to the reaction eg, methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane or benzene
- the compound represented by the formula (XXXI *) is hydrogenated at a temperature between 0 ° C. and the boiling point of the reaction mixture, preferably at room temperature, to obtain a reduced form.
- a solvent for example, a mixed solvent of tetrahydrofuran / water, a mixed solvent of ethyl ether / water, a mixed solvent of dioxane / water, a mixed solvent of methanol / water, and ethanol
- a solvent for example, a mixed solvent of tetrahydrofuran / water, a mixed solvent of ethyl ether / water, a mixed solvent of dioxane / water, a mixed solvent of methanol / water, and ethanol
- Water mixed solvent at room temperature and at the temperature between the boiling points of the reaction mixture, preferably at room temperature, lithium hydroxide, sodium hydroxide, lithium hydroxide + hydrogen peroxide, sodium hydroxide + hydrogen peroxide, tetra Treatment with butylammonium hydroxide + hydrogen peroxide gives the carboxylic acid.
- a catalyst eg, palladium on activated carbon, palladium hydroxide, platinum oxide or a Wilkinson catalyst
- a solvent inert to the reaction eg, methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane) Or in benzene
- a solvent inert to the reaction eg, methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane
- benzene eg, benzene
- Reaction Scheme 8 (Method 8), Reaction Scheme 9 (Method 9), and Reaction Scheme 10
- R in the formula (XXX IV *) represents an alkyl group.
- a solvent inert to the reaction eg, tetrahydrofuran, toluene, gel A compound represented by the formula (XX XV *) in butyl ether, hexane, preferably tetrahydrofuran
- a temperature between ⁇ 78 ° C. and the boiling point of the reaction mixture preferably ⁇ 30 ° C. to room temperature.
- a base eg, lithium diisopropylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, butyllithium
- a base eg, lithium diisopropylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, butyllithium
- a solvent inert to the reaction eg, Methanol, ethanol, tetrahydrofuran, water, preferably a mixed solvent of tetrahydrofuran / water
- a solvent inert to the reaction eg, Methanol, ethanol, tetrahydrofuran, water, preferably a mixed solvent of tetrahydrofuran / water
- Ethyl 10_ [(3R, 4R) -7-me thoxy-3- (4-me thoxypheny 1)-3-me thyl thi ochroman-4- yl] -2- (4, 4, 5, 5, 5-pentaf luoropentyl) -8-decenoate (3.46 g, 5.268 mmol) in tetrahydrofuran (60 ml), 10% Pd / C (1.04 g) was added, and the mixture was stirred at room temperature under a stream of hydrogen. For 23 hours.
- Ethyl 10- [(3R, 4R) -7-Hydroxy-3- (4-hydroxypenyl) -3-methylthiochroman-4-yl] -2- (4,4,5,5,5-pentafluoropentyDdecanoate (2.08 g, 3.297 bandol) and sodium hydroxide (527 mg, 13.19 ol) were added to a mixed solvent of ethanol / water (40/10 ml), and the mixture was heated under reflux for 4 hours.
- (+)-7-Hydroxy-3- (4-hydroxyphenyl) -3-methylchroman-4-one was resolved by chiral column (CHIRALCEL 0D), and (+)-7_Hydroxy-3- (4-hydroxyphenyl)-3 - Mehtylchroman-4-one and (-)-7-Hydroxy-3- (4-hydroxyphenyl) -3- 3-mehtylchroman-4-one were obtained.
- (+)-7-Hydroxy-3- (4-hydroxyphenyl) -3-methylchroman-4-one (2.0 g, 7.40 mmol) in anhydrous tetrahydrofuran (30 ml) was cooled to -78 ° C and hydrogenated.
- a toluene solution of diisobutylaluminum (1N, 22.94 ml, 22.94 ol) was slowly dropped, and the mixture was stirred at -78C for 35 minutes. -78 in the reaction solution.
- C. Methanol (1 ml) was added and the temperature was raised to 0 ° C.
- Example 4 Without Protecting the Hydroxyl Group of the Optically Active 7-Hydroxy-3- (4-hydroxypheny1) -3-methhy1-4- (2-propenyl) chroman Obtained in the First Step Alternatively, synthesis is performed in the same manner as in Example 5, and the 3- and 4-positions have a chiral cis configuration 11- [7-Hydroxy-3- (4-hydroxyphenyl) -3-methylchro--4--4-yl "- 2-(4, 4, 5, 5, 5-pentafluoropentyDundecanoic Acid was obtained.
- Optically active compound 3 (211 mg) obtained in the first step and (3RS, 4RS) -7-Hydroxy-3- (4-hydroxyphenyl) -3-methyl-4- (2-propenyl) chroman 4 (racemic , 59 mg), and subjected to the same method as in Example 7 to obtain 125 mg of a coupled product.
- This coupling product was hydrogenated in the same manner as in Example 7 to obtain 87 mg of a reduced product .
- a 1M aqueous solution of lithium hydroxide (0.15 ml) was added to a solution of the obtained reduced form (20 mg) in tetrahydrofuran (0.5 ml), and the mixture was stirred at 50 ° C for 1 day.
- reaction mixture was acidified with 2N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
- the obtained compound 5 was analyzed under the following conditions. In the racemic form, four kinds of peaks (retention time 9,3, 10.2, 16.5, 29.9 min) were observed, whereas compound 5 obtained here had two kinds of peaks (retention time 9.3, 16.5 min). ) was observed.
- the first peak had a retention time of 10.1 minutes, and the second peak had a retention time of 13.5 minutes.
- the first peak has a retention time of 9.5 minutes, and the second peak has a retention time of 10.9 minutes. there were.
- Measurement wavelength 254nm
- Test example 1 Anti-estrogenic activity test (oral administration)
- Anti-estrogenic activity was measured by subcutaneously injecting 173-estradiol benzoate (Sigma) into mice (ICR, body weight 30 ⁇ 2 g) 2 weeks after ovariectomy surgery at 0.1 g per mouse for 3 days. This was done by measuring the extent to which the test compound inhibited uterine weight gain. In this test, the test compound and the control compound were suspended in a 5% gum arabic solution and orally administered once daily for 3 days. At 24 hours after the final administration, the test animals were sacrificed, the uterus was removed, and the weight was measured. The measurement results are shown in Table 2 below.
- the compounds according to the invention substantially inhibit estradiol-induced increase in uterine weight, to a much greater extent than the corresponding racemic mixtures.
- the compounds of the present invention exhibit anti-estrogenic activity and the like, and are particularly useful as medicaments, since they can provide considerably better anti-estrogenic activity than racemic mixtures.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00981678A EP1241165A4 (en) | 1999-12-13 | 2000-12-13 | OPTICALLY ACTIVE CHROMANE AND THIOCHROMANE DERIVATIVES |
AU18880/01A AU1888001A (en) | 1999-12-13 | 2000-12-13 | Optically active chroman and thiochroman derivatives |
US10/149,748 US6610733B2 (en) | 1999-12-13 | 2000-12-13 | Optically active chroman and thiochroman derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35341399 | 1999-12-13 | ||
JP11/353413 | 1999-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001042233A1 true WO2001042233A1 (fr) | 2001-06-14 |
Family
ID=18430679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/008807 WO2001042233A1 (fr) | 1999-12-13 | 2000-12-13 | Derives de chromane et de thiochromane optiquement actifs |
Country Status (4)
Country | Link |
---|---|
US (1) | US6610733B2 (ja) |
EP (1) | EP1241165A4 (ja) |
AU (1) | AU1888001A (ja) |
WO (1) | WO2001042233A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1241166A4 (en) * | 1999-12-13 | 2003-04-16 | Chugai Pharmaceutical Co Ltd | 3-MEHTYL CHROMAN AND THIOCHROME DERIVATIVES |
AU780947B2 (en) * | 1999-12-13 | 2005-04-28 | Chugai Seiyaku Kabushiki Kaisha | Compound having hydroxycarbonyl-halogenoalkyl side chain |
US6963002B2 (en) * | 2003-07-04 | 2005-11-08 | Glenmark Pharmaceuticals Limited | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman |
US8080675B2 (en) * | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
ATE532777T1 (de) | 2004-09-21 | 2011-11-15 | Marshall Edwards Inc | Substituierte chromanderivate, medikamente und anwendungen in der therapie |
CA2816322A1 (en) | 2010-11-01 | 2012-05-10 | Marshall Edwards, Inc. | Isoflavonoid compositions and methods for the treatment of cancer |
AU2016215515B2 (en) | 2015-02-02 | 2020-04-30 | Mei Pharma, Inc. | Combination therapies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025916A1 (en) * | 1996-12-13 | 1998-06-18 | C & C Research Laboratories | Novel benzopyran derivatives |
WO1999065893A1 (en) * | 1998-06-13 | 1999-12-23 | C & C Research Laboratories | Novel benzopyran or thiobenzopyran derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5675024A (en) * | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
US6316494B1 (en) * | 1996-10-28 | 2001-11-13 | Novo Nordisk A/S | cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
EP1043322B1 (en) * | 1997-12-24 | 2002-05-08 | Senju Pharmaceutical Co., Ltd. | Vitamin e derivatives |
TW546150B (en) * | 1998-01-28 | 2003-08-11 | Pola Chem Ind Inc | External agent composition for the skin |
RU2232758C2 (ru) * | 1998-09-23 | 2004-07-20 | Рисерч Дивелопмент Фаундейшн | Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием |
-
2000
- 2000-12-13 AU AU18880/01A patent/AU1888001A/en not_active Abandoned
- 2000-12-13 WO PCT/JP2000/008807 patent/WO2001042233A1/ja not_active Application Discontinuation
- 2000-12-13 EP EP00981678A patent/EP1241165A4/en not_active Withdrawn
- 2000-12-13 US US10/149,748 patent/US6610733B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025916A1 (en) * | 1996-12-13 | 1998-06-18 | C & C Research Laboratories | Novel benzopyran derivatives |
WO1999065893A1 (en) * | 1998-06-13 | 1999-12-23 | C & C Research Laboratories | Novel benzopyran or thiobenzopyran derivatives |
Non-Patent Citations (1)
Title |
---|
See also references of EP1241165A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1241165A1 (en) | 2002-09-18 |
US6610733B2 (en) | 2003-08-26 |
EP1241165A4 (en) | 2003-03-19 |
US20030125571A1 (en) | 2003-07-03 |
AU1888001A (en) | 2001-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3954386B2 (ja) | 抗エストロゲン作用を有する4−フルオルアルキル−2h−ベンゾピラン | |
JP3357356B2 (ja) | ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物 | |
WO2001042233A1 (fr) | Derives de chromane et de thiochromane optiquement actifs | |
JP2003525285A (ja) | エストロゲン化合物としてのクロマン誘導体 | |
US6552068B1 (en) | 3-ethyl-, 3-propyl- or 3-butyl-chroman and thiochroman derivatives | |
KR20020073179A (ko) | 칼실리틱 화합물 | |
JP2001502706A (ja) | エストロゲン関連病あるいは症候群の予防または治療に有用な新規トランス―3,4クロマン誘導体 | |
US6552069B1 (en) | 3-methyl-chroman and -thiochroman derivatives | |
ZA200100201B (en) | Novel antiestrogens, a method for the production thereof, and their pharmaceutical application. | |
US6555571B2 (en) | 3-methyl -chromane or thiochromane derivatives | |
US20030092695A1 (en) | Metal salts of 3-methyl-chromane or thiochromane derivatives | |
JP5054882B2 (ja) | テトラヒドロベンズフルオレン誘導体 | |
JP4798924B2 (ja) | ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物 | |
JPH02743A (ja) | 新規化合物およびその医薬的用途 | |
JP2005314357A (ja) | 4級アンモニウム化合物、その製造方法及び脳血管障害治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 543532 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000981678 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10149748 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000981678 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000981678 Country of ref document: EP |